[BACK TO TOP]
A
.
LOOK-ALIKE/SOUND-ALIKE EFFORTS
1.
Alerts
PBM WARNING
LETTER: Sulfasalazine and Sulfadiazine LA/SA Errors
Warning Letter - Sulfasalazine-Sulfadiazine
LA-SA Errors
Look-Alike Sound-Alike Confusion Potential with Humapen
Memoir® and Humira® Pen – January 2007
Two Pens Different Uses; PBM
Ez-Minutes January – March 2007
HUMIRA Pen and HumaPen;
ISMP Newsletter April 2007
Look-Alike Sound-Alike Vaccine Mix-ups: Adacel (Tdap) and Daptacel (DTaP)
– August 24, 2006
ISMP Newsletter
Fluarix® and Twinrix® Look-Alike
Confusion Potential
National PBM Bulletin -
Look-Alike Safety Alert Regarding Fluarix®
and Twinrix®
LOOK-ALIKE SAFETY ALERT FOR HALOPERIDOL AND CYANOCOBALAMIN
1ML VIALS
National PBM Bulletin
2. Pilot
Project for Determining Look-alike Sound-alike Drug Names for New
Molecular Entities (NMEs)
a.
LASA Draft Paper
b.
Appendix I
c.
Appendix 2
d.
Appendix 3
3.
Database
Evaluations/Tool
a.
General Information and Evaluation s for NMEs
4.
VA-Specific LASA pairs
a.
Cumulative VA LASA list
b.
VA LASA list 2010
5. Institute for Safe Medication
Practice
a.
ISMP Confused Drug Name
b.
Reported LASA in ISMP Newsletters 2010
6. USP
LA/SA list – USP Quality Review, March 2001, No. 76: Use Caution – Avoid Confusion
[BACK TO TOP]
B. PHARMACOVIGILANCE
AND DRUG SAFETY PROJECTS
1.
GENERAL SAFETY PROJECTS/PILOT PROJECTS
a. Adverse
Drug Event (ADE) Reporting
b. Look-Alike
Sound-Alike (LA/SA) Drug Names for New Molecular Entities (NMEs)
c. Active
Surveillance – Signal Detection
2.
SITE-BASED MEDICATION SAFETY EVALUATIONS
a. Conversion to and Initiation with Travoprost in Glaucoma Management
b. Erythropoeitin Stimulating Agents (ESA) Database Medication
Use Evaluation (MUE) Tracker
c. Evaluation of Amiodarone Monitoring
3.
RISK REDUCTION PROJECTS
a. Glyburide Use in Patients with Renal Insufficiency
b. High Dose Zolpidem
c. High Dose Atypical Antipsychotic
4.
DRUG SURVEILLANCE/PHARMACOVIGILANCE PROJECTS (Ongoing)
a. Polypharmacy in Post Traumatic Stress Disorder (PTSD)
b. Atypical Antipsychotic/SSRI/Benzodiazepine
Rapid Cycle Analysis
c.
Varenicline Rapid Cycle Analysis
d. PPIs Rapid Cycle Analysis
e. Rapid Cycle Evaluation of Thiazolidinediones
f. Long-Acting Opioids
g. Bisphosphonates Pharmacovigilance-Rapid Analysis
h. Rapid Cycle Analysis: Bevicizumab and Ranibizumab
i. Rapid Cycle Signal Strengthening Evaluation: PPIs,
H2Bs, and ACEs
j. Rapid Cycle Analysis - Antiviral Drugs: Amantadine, Oseltamivir,
Rimantadine, and Zanamivir
k. Osteoporosis
l. Vaccine Safety
m. Influenza Project
n. Risperidone
o. Varenicline
p. Beta-Blockers
q. Glyburide
r. Warfarin
s. Fluoroquinolones
[BACK TO TOP]
C. POLICIES
1.
Pharmaceutical Use Outside of Approved Indications Guidance on Off-Label Prescribing
[BACK TO TOP]
D. DRUG MARKET WITHDRAWALS
1.
Rofecoxib (Vioxx®)
a.
PBM Bulletin/News Alert
b.
Physician Notification Letter
c.
Pharmacist Notification Letter
d.
Dear Healthcare Provider Letter
e.
FAQ’s
f.
Patient
Letter
2. Valdecoxib (Bextra®)
a.
Guidance
b.
Patient
Letter
3. Natalizumab (Tysabri®) – February
2005 - June 2006
a.
FDA Public Health Advisory
b.
FDA Alert – Information for Healthcare Professionals
c.
Dear Healthcare Professional Letter – March 2005
d.
Dear Healthcare Professional Letter – April 2005
e.
FAQ’s on the Clinical Hold
f.
FAQ’s on Natalizumab
g.
Prescribing Information
h.
PBM Removal Communication and Actions
i.
Important Drug Warning Letter from Biogen/Idec, Elan
j.
FDA Information on resumed market
4. Gatifloxacin (Tequin®)
a.
Letter of Discontinuation from Bristol Myers Squibb – May 2006
b.
FDA Alert – Information for Healthcare Professionals – March 2006
c.
FDA Alert – Patient Information – March 2006
d.
Prescribing Information
5. Mivacurium (Mivacron®)
a. FDA Drug Shortages
6.
Tegaserod (Zelnorm®) and Discontinued Marketing
– March 30, 2007
a. FDA News
b. Questions
and Answers on Zelnorm
c. FDA Public Health
Advisory
d. National
PBM Bulletin
e. Tegaserod
Provider Letter
f.
Tegaserod Patient Letter
g. Restricted Use
of Zelnorm – July 2007
7.
FDA Recalls, Market Withdrawals, Safety
Alerts
|
